Franchise Directory

Chronic pain affects more than 50 million adults in the United States, making it one of the most prevalent and economically costly health conditions in the country — and yet the dominant treatment paradigm for decades has relied on opioid prescriptions and surgical interventions that carry enormous risks, staggering costs, and deeply uncertain long-term outcomes. Anodyne Pain Wellness Soluti was built to solve exactly that problem. The parent company, Anodyne Pain & Wellness Solutions, Inc., was incorporated on October 3, 2018, in Nashville, Tennessee, where it maintains its principal business address at 2 Music Circle South, Suite 101. The franchising arm, Anodyne Franchising, LLC, was established on November 7, 2019, and began offering franchise opportunities on August 1, 2020, making this a relatively young but rapidly structured franchise system with deliberate corporate architecture separating the operating entity from the growth vehicle. The brand's clinical philosophy centers on non-opioid, non-surgical treatment of both acute and chronic pain through a medically integrated, full-spectrum care model that combines physical medicine, traditional medicine, functional medicine, and regenerative medicine under one roof. In March 2021, Greg Simons joined as Chief Executive Officer and Gregg Rondinelli assumed the role of President of Anodyne Franchising, LLC, arriving at a moment when the organization had already reached a reported footprint of 37 locations encompassing both corporate-owned and franchised clinics. The Anodyne Pain Wellness Soluti franchise opportunity sits within the "All Other Outpatient Care Centers" category, a segment of the broader global outpatient clinics market that was valued at USD 87.31 billion in 2023. For franchise investors evaluating positions in the health and wellness sector, this brand occupies a distinctive niche: it targets one of the largest chronic condition populations in America with a care model that is explicitly designed to reduce reliance on the treatments — opioids, surgery — that drive the highest healthcare costs and the most adverse outcomes. This analysis is independent research, not marketing content, and it examines the Anodyne Pain Wellness Soluti franchise investment from a data-driven investor perspective. The macroeconomic tailwinds behind the Anodyne Pain Wellness Soluti franchise opportunity are substantial and secular in nature. The global outpatient clinics market, the competitive arena in which Anodyne operates, was valued at USD 87.31 billion in 2023 and is projected to reach USD 133.94 billion by 2032, representing a compound annual growth rate of 4.87% from 2024 to 2032. North America is expected to dominate this market over the entire forecast period, which means domestic Anodyne franchisees are operating in the highest-value geographic segment of a globally expanding industry. Several structural forces are accelerating this growth simultaneously: an aging U.S. population increasingly burdened by chronic musculoskeletal conditions and neuropathic pain, a national reckoning with opioid dependency that has created both regulatory pressure and patient demand for alternative pain management pathways, and a broader shift in healthcare delivery from expensive inpatient settings to cost-effective outpatient environments. The integration of digital health technologies — including telemedicine, electronic health records, remote patient monitoring, and mobile health applications — is transforming the operational efficiency of outpatient clinics and expanding their geographic reach beyond traditional brick-and-mortar limitations. Anodyne moved proactively in this direction by launching a behavioral health telemedicine pilot program in select clinics in the first quarter of 2022, with expansion of that service planned across all corporate and franchise locations. The acquisition of Insight Physician Associates in October 2021 — a Virginia-based behavioral health practice group with a 15-person provider team including 5 psychiatrists — was a direct strategic response to clinical evidence linking unresolved mental health conditions to chronic pain persistence. The market for non-opioid pain management is not a niche trend; it is a structural realignment of how American healthcare approaches one of its most costly and widespread conditions, and Anodyne has organized its entire clinical model around that realignment. The Anodyne Pain Wellness Soluti franchise cost structure places this investment in a mid-to-upper tier of the health services franchise category. The total initial investment range runs from $121,400 on the low end to $608,000 at the high end, a spread that reflects meaningful variability in format type, geographic market, lease terms, build-out requirements, and whether a franchisee is establishing a new clinic versus converting an existing pain management practice to the Anodyne brand. The system is explicitly structured to accommodate both pathways — new clinic development and brand conversion — which creates genuine flexibility in how capital is deployed. The initial franchise fee reaches up to $60,000, a figure that is consistent with premium health services franchise systems where proprietary clinical protocols, medical staffing networks, and regulatory compliance infrastructure add meaningful value to the licensing relationship. Ongoing fees include a royalty rate of 6.0% of gross revenues, which is standard for medically integrated franchise systems, and an advertising fund contribution of 2.0% of gross revenues, bringing the combined ongoing fee obligation to 8.0% of top-line revenue. Franchise agreement terms are structured with an initial 10-year term and a 5-year renewal option, providing long-runway operational security for franchisees making a significant capital commitment. Liquid capital requirements of $250,000 reflect the working capital demands of building a clinical practice to steady-state operations, including physician credentialing timelines, insurance network contracting, and the ramp period before patient volume reaches breakeven. It is worth noting that the investment range published in the Franchise Disclosure Document — $417,215 to $460,715 per some FDD-sourced data — differs from the broader $121,400 to $608,000 range appearing in other franchise database sources, which suggests that format-specific or market-specific variables create meaningful cost divergence that prospective franchisees should investigate directly with the franchisor. Anodyne's corporate backing through parent entity Anodyne Pain & Wellness Solutions, Inc. and the leadership team assembled in 2021 — including a dedicated Chief Marketing Officer in Lou Imbriano — provide institutional support infrastructure for franchisees that newer or less capitalized franchise systems cannot replicate. The daily operational reality of an Anodyne Pain Wellness Soluti franchise reflects a clinically sophisticated, team-based care delivery model that distinguishes it fundamentally from single-modality health service franchises. Each Anodyne clinic is staffed by a multidisciplinary team that includes physicians board-certified in pain management, anesthesiology, neurology, sleep medicine, and headache medicine, working alongside behavioral therapists, nurses, and additional clinical and administrative staff who collaborate to develop individualized treatment plans for each patient. This staffing model requires careful recruitment, credentialing, and management, and Anodyne addresses the complexity directly: the franchise system is explicitly designed to allow non-medical providers to develop new clinic locations, meaning that franchisees without clinical backgrounds can own and operate a location by building the appropriate medical team rather than practicing medicine themselves. Regan Archibald, a licensed acupuncturist and functional medicine practitioner who manages five Anodyne locations in Utah, publicly noted that he is available to walk prospective franchisees without medical backgrounds through the hiring process, demonstrating that the system has operationalized a pathway for non-clinician ownership. Training is conducted through a dual-phase program beginning at Anodyne's corporate headquarters in Nashville, Tennessee, and ongoing support covers unit operations, customer service techniques, administrative practices, and supply chain coordination, with the franchisor actively negotiating quantity discounts on essential inventory items including syringes, signage, and marketing supplies. Franchisees receive exclusive territories determined on the basis of population metrics, a structure that provides geographic protection for patient acquisition and prevents intra-system cannibalization. Anodyne's operational support extends for the entire life of the franchise agreement, reflecting a commitment to franchisee-level performance that is foundational to the system's long-term ambition of becoming the world leader in functional, physical, and regenerative medicine. The company's expansion of services to include behavioral health through telemedicine — piloted in Q1 2022 and intended for systemwide rollout — adds a recurring-revenue service line that can be delivered remotely, reducing the incremental operational burden of service expansion. Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for the Anodyne Pain Wellness Soluti franchise. This is a significant gap for prospective investors and warrants careful attention during the due diligence process, as the absence of Item 19 disclosure means investors cannot rely on franchisor-published benchmarks for average revenue, median performance, or top-quartile earnings to construct pro forma financial models. However, publicly available data points provide meaningful reference anchors. An earlier FDD-cycle Item 19 disclosure cited average revenue per unit of $2,024,713 and average gross profit per unit of $1,355,539 for 2020, figures that if representative of current performance would indicate exceptional unit economics — a gross margin of approximately 67% on a per-unit basis is consistent with high-value medical services businesses where provider expertise, not physical inventory, is the primary value driver. The company's estimated annual revenue is approximately $9.9 million, with an estimated revenue per employee of $216,000, which reflects the high-productivity economics of medically integrated outpatient care. Industry-level benchmarks for outpatient pain management and regenerative medicine clinics suggest that well-operated multi-specialty practices in mid-to-large metropolitan markets can achieve annual revenues in the $1.5 million to $3 million range, with EBITDA margins in the 15% to 25% range depending on provider compensation structures and payer mix. The acquisition of Integrated Pain Consultants in July 2022 — an Arizona-based practice founded in 2015 by Dr. Nikesh Seth comprising four Phoenix-area clinics and two ambulatory surgery centers — adds a validated revenue model from an established multi-site pain management group to the Anodyne corporate ecosystem, providing internal benchmarking data that should eventually surface in future FDD disclosures. The Anodyne Pain Wellness Soluti franchise revenue story is still being written at the unit level, and prospective investors should request detailed financial validation from existing franchisees, a process protected by FDD Item 20 contact disclosures, and should independently engage a healthcare-specialized CPA to model realistic pro forma scenarios before committing capital. The growth trajectory of the Anodyne Pain Wellness Soluti franchise reflects both genuine expansion momentum and the inherent complexity of scaling a medically integrated service business. The company reported 12 corporate locations and 25 franchise locations as of December 2020, just months after formally launching its franchise offering on August 1, 2020 — a pace of franchise sales that indicated substantial early market interest. Planned franchise locations at that time spanned a broad geographic footprint including Wilmington, Delaware; St. Louis, Missouri; Boise, Idaho; Jackson, Mississippi; West Palm Beach and Boca Raton, Florida; four locations in New Hampshire; six in Massachusetts; three in Nevada; two in Texas; four in Arizona; and additional Utah locations complementing the four already operating. Current database sources, however, reflect five existing franchised units with zero company-owned locations, a divergence from early reported numbers that franchise investigators should probe carefully — discrepancies between announced franchise sales and operational unit counts are common in emerging franchise systems where some signed agreements do not progress to open locations. The PeerSense FPI Score of 53 for this franchise, classified as Moderate, reflects this mixed signal environment: a genuinely differentiated clinical model and strong industry tailwinds balanced against a relatively limited current footprint and an evolving disclosure history. Leadership investments made in March 2021 — CEO Greg Simons, President Gregg Rondinelli, and CMO Lou Imbriano joining simultaneously — represent a deliberate institutional upgrade designed to accelerate systemwide growth. The July 2022 addition of Dr. Nikesh Seth as Chief Medical Officer following the Integrated Pain Consultants acquisition brings direct clinical credibility and multi-site operational experience to the leadership team. Anodyne's long-term competitive moat rests on its proprietary full-spectrum care protocols, its exclusive territory structure, its medically integrated staffing model that is difficult to replicate without institutional knowledge transfer, and its strategic expansion into behavioral health telemedicine, which positions the brand ahead of the broader market shift toward integrated mental and physical health treatment. The ideal Anodyne Pain Wellness Soluti franchisee candidate does not need a clinical background to enter the system — the operational model is specifically architected to allow non-medical entrepreneurs to build and manage a clinical team under the Anodyne brand protocols. What the system does require is significant management capability, financial resources meeting the $250,000 liquid capital threshold, and the organizational sophistication to recruit, credential, and retain board-certified physicians and licensed behavioral health providers in a competitive healthcare labor market. Multi-unit ownership is a natural strategic extension of this model given the fixed cost of building a medical network in a given geography, and Regan Archibald's management of five Utah locations provides a working proof-of-concept for the multi-unit Anodyne operator. Geographic expansion targets, as articulated by the franchisor, focus initially on major U.S. metro markets with plans to subsequently penetrate secondary and tertiary markets, with the ultimate goal of establishing an Anodyne Pain & Wellness clinic in every state nationwide. Available territories span the majority of the country given the current five-unit footprint, which means franchise investors are evaluating a ground-floor position in a system with stated national ambitions and substantial white space. The franchise agreement runs for an initial 10-year term with a 5-year renewal option, providing a minimum 15-year operational horizon for investors who execute the renewal, and the system's conversion pathway for existing pain management practices means that experienced healthcare operators can enter the brand with an existing patient base and revenue stream rather than building from zero. The investment thesis for the Anodyne Pain Wellness Soluti franchise rests on four convergent factors: a structurally undersupplied market for non-opioid, non-surgical pain management in a country of 50 million chronic pain sufferers; an outpatient clinics industry growing from USD 87.31 billion in 2023 toward USD 133.94 billion by 2032; a corporate leadership team assembled in 2021 and 2022 with deliberate senior hires across the CEO, President, CMO, and CMO roles; and a clinical model that integrates physical, functional, traditional, and regenerative medicine with behavioral health telemedicine in a way that no single-modality competitor can replicate at scale. The PeerSense FPI Score of 53 reflects the moderate risk profile appropriate to an emerging franchise system with genuine clinical differentiation and a growing but still-limited operational track record — it is a score that demands serious due diligence, not dismissal. Investors with healthcare management experience, entrepreneurial capital above the $250,000 liquid threshold, and interest in a healthcare franchise opportunity positioned at the intersection of chronic disease management and the broader shift away from opioid dependency will find the Anodyne Pain Wellness Soluti franchise investment worthy of deep investigation. PeerSense provides exclusive due diligence data including SBA lending history, FPI score analysis, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark this franchise against peer concepts across the outpatient care and health and wellness categories. Explore the complete Anodyne Pain Wellness Soluti franchise profile on PeerSense to access the full suite of independent franchise intelligence data and make your investment decision from a position of maximum information.

Cryofit

All Other Outpatient Care Centers

49

Fair

Navigating the complex and rapidly evolving health and wellness industry for a franchise investment presents a significant challenge for discerning entrepreneurs, who seek not just a business, but a pathway to sustained growth and impact without the pitfalls of unproven models or fragmented markets. Understanding the true potential of a Cryofit franchise opportunity requires a deep dive into its foundational history, strategic evolution, and current market positioning. CryoFit, originally established in Austin, Texas, in 2014 by co-founders Sheryl Reeh and Brian Balli, has recently undergone a transformative rebranding to "bioworX: Essentials for Life." This strategic pivot signifies an expansion of its mission beyond its initial pioneering wellness services, now aiming to deliver comprehensive, science-based wellness solutions through an integrative approach encompassing twelve unique modalities. While the corporate address for CryoFit Americas, Inc. remains 1406 Camp Craft Rd., Suite 112, Austin, Texas 78746, and Jeff Reeh is listed as its CEO, the operational focus has shifted significantly under the bioworX banner, where Brian Balli now serves as President & Co-Founder. The original CryoFit brand began offering franchises in 2017 and had grown to 11 locations by February 2023, primarily concentrated in Texas with some presence in Wisconsin; following the rebranding, bioworX has expanded its footprint to 14 locations nationwide, demonstrating a continued growth trajectory despite the ambitious initial goals of the founders in 2015 to reach 50 locations within two years and 250 within five years not being met. However, for the specific legacy "Cryofit" brand, independent database records indicate a current count of 2 total units, both of which are franchised and none are company-owned, reflecting a distinct operational snapshot within its broader evolution. This brand matters to franchise investors by offering a foothold in the booming $4.5 trillion global wellness industry, positioning itself as a guide for entrepreneurs looking to optimize performance and support natural healing processes through cutting-edge modalities. PeerSense provides this independent analysis, meticulously dissecting the brand's profile to offer an authoritative perspective, distinctly separate from any marketing claims. The industry landscape in which bioworX (formerly CryoFit) operates is characterized by robust growth and evolving consumer preferences, offering significant tailwinds for well-positioned franchise concepts. The global cryotherapy market, a core segment of bioworX's offerings, was valued at $6.39 billion in 2021 and is projected to advance at a compound annual growth rate (CAGR) of 7.2% by 2030, indicating a consistent expansion of demand for these specialized services. Alternative market analyses further underscore this growth, with projections placing the market size at $207.5 million in 2024, anticipated to reach $325.3 million by 2030, growing at a CAGR of 7.8% from 2025 to 2030. Mordor Intelligence provides another perspective, estimating the market size to increase from $322.04 million in 2025 to $464.61 million by 2031, with a CAGR of 6.45% over 2026-2031. North America leads this market, commanding a substantial revenue share of 57.4% in 2024, with the U.S. market alone accounting for an impressive 89.4% of the North American segment, highlighting a concentrated and lucrative domestic opportunity. Cryochambers dominate the product segment, holding a 51.7% share in 2024, while beauty and wellness applications drive demand with a 32.5% revenue share, and cryotherapy centers themselves capture the largest end-use market share at 48.8% in 2024. Beyond cryotherapy, the broader global outpatient care market, which encompasses many of bioworX's integrative services, was valued at approximately $48.5 billion in 2024 and is predicted to surge to around $157.5 billion by 2034, exhibiting a significant CAGR of roughly 12.5% between 2025 and 2034. This growth is fueled by key consumer trends, including an increasing preference for convenience, cost-effectiveness, and quicker access to healthcare services, alongside a rising recognition of cryotherapy's benefits for pain management, muscle recovery, and overall wellness. The market is also witnessing a shift towards non-invasive treatments to reduce risks associated with traditional surgeries, further broadened by increased sports participation and social media promotion. These secular tailwinds create a fertile ground for a franchise like bioworX, which offers a diversified portfolio of science-based wellness solutions, positioning it to capitalize on a market that, while fragmented, is increasingly consolidating around comprehensive, integrative approaches. For a potential investor considering the Cryofit franchise cost and overall Cryofit franchise investment, a detailed understanding of the financial requirements is paramount. The initial franchise fee for a CryoFit (now bioworX) unit is reported with slight variations, with one source indicating a minimum and maximum upfront franchise fee of $35,000, while another specifies a franchise fee of $39,000 for CryoFit. This fee represents the upfront cost for the rights to operate under the brand's system and access its proprietary knowledge. The total investment necessary to begin operation of a CryoFit facility has also seen varying figures, with one range cited from $141,550 to $289,000, and another providing a broader estimate of $275,000 to $350,000. Following the rebranding and expansion of modalities, the total investment for a bioworX franchise ranges from $299,050 to $446,700, reflecting the enhanced scope of services and facility requirements. These comprehensive costs typically include the initial franchise fee, essential equipment, initial marketing expenditures to launch the business, and crucial working capital to sustain operations during the initial ramp-up phase. Beyond the initial outlay, franchisees are subject to ongoing fees, including a royalty rate structured as 6% of gross sales, paid semi-monthly, which aligns with general industry information suggesting royalties typically range from 4-8% of gross sales. Additionally, franchisees contribute to a system-wide advertising fund, remitting 1% of gross sales semi-monthly, to support collective brand promotion and marketing initiatives. Prospective franchisees are also required to meet specific liquid capital and net-worth thresholds to ensure financial stability. The minimum cash required is reported as $250,000 or $257,000, indicating a substantial liquid asset requirement. Furthermore, a net-worth requirement of $350,000 is specified for potential owners, demonstrating the brand's preference for financially robust candidates. In terms of financing, bioworX is recognized as an SBA-approved franchise, which facilitates access to Small Business Administration lending programs, allowing prospective owners to collaborate with participating financial institutions. Given these financial parameters, the Cryofit franchise investment positions itself as a mid-tier to premium opportunity within the wellness sector, requiring significant capital but offering the backing of an established and evolving brand. The operational model and comprehensive support system offered by bioworX, formerly CryoFit, are designed to empower franchisees from the outset, mitigating the inherent risks associated with launching a new business. The franchisor emphasizes a commitment to providing extensive training and robust corporate support, ensuring that new owners are well-equipped to manage their wellness centers effectively. Daily operations for a franchisee involve managing a diverse range of science-based wellness modalities, including whole-body cryotherapy, IV drip infusions, infrared saunas, injectable vitamins, and compression boots, alongside the twelve unique modalities introduced under the bioworX brand. The brand boasts a low overhead operating model, coupled with in-depth training and a proven business framework. The training program is an intensive, hands-on experience conducted at a corporate facility in San Antonio, covering a wide array of critical operational aspects. These sessions comprehensively address business management strategies, effective marketing and social media deployment, the intricacies of facility and equipment operations and maintenance, essential cost management techniques, and the specialized control and purchasing of nitrogen gas. This holistic approach ensures franchisees gain a deep understanding of both the business and technical facets of their wellness center. In terms of ongoing support, CryoFit assists new owners with crucial location criteria, leveraging its network to help them find commercial real estate brokers in their target areas to aid with lease negotiations. Support extends through the construction and design phases of the facility, providing guidance to ensure brand consistency and operational efficiency. While the brand prefers franchisees to be actively involved in their store's operations, reflecting an owner-operator model, it is not a mandatory requirement, offering flexibility for multi-unit developers or those with strong management teams. Multi-unit development opportunities are explicitly available, indicating the brand's scalability and suitability for ambitious entrepreneurs looking to expand their portfolio. The bioworX brand specifically underscores its robust business model, comprehensive training programs, and premier marketing support, all meticulously designed to ensure long-term franchisee success within the competitive wellness market. Regarding financial performance, potential investors in a Cryofit franchise should note that Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for Cryofit. This means specific profit figures for CryoFit franchise owners are not publicly available through the FDD. Under the Federal Franchise Rule, franchisors are not legally mandated to provide earnings information in Item 19 of their Franchise Disclosure Document. However, if any financial performance claims are made, they must be meticulously disclosed and substantiated within this section. It is important to understand that Item 19 may include various financial metrics such as revenue, sales, expenses, or profit information, but revenue data alone does not definitively indicate profitability. The absence of publicly available profit data necessitates that potential franchisees conduct exceptionally thorough due diligence and engage directly with the franchisor for any Item 19 disclosures that may be available, and critically, to speak with existing franchisees. Despite the lack of specific profit disclosures, several market and operational indicators can offer insights into the potential for Cryofit franchise revenue generation. The global wellness industry, valued at $4.5 trillion, provides a vast addressable market, with the cryotherapy market alone projected for significant growth, advancing at a CAGR of 7.2% by 2030 from its $6.39 billion valuation in 2021. Other forecasts show the cryotherapy market reaching $325.3 million by 2030 with a 7.8% CAGR from 2025-2030, or $464.61 million by 2031 with a 6.45% CAGR over 2026-2031, suggesting a healthy and expanding revenue environment. The broader global outpatient care market, valued at $48.5 billion in 2024, is predicted to grow to $157.5 billion by 2034, exhibiting a substantial CAGR of 12.5% between 2025 and 2034, further highlighting the robust demand for services offered by bioworX. Historically, CryoFit began franchising in 2017, and by February 2023, it had grown to 11 locations, which then expanded to 14 locations nationwide under the bioworX brand. While the founders' initial ambitious goals of 50 locations within two years and 250 within five years in 2015 were not realized, the consistent growth in unit count from its founding to its current state under bioworX suggests a steady, albeit measured, expansion. Franchisee testimonials, such as Chelsea J., who bought her first CryoFit in August 2019 and opened a second in February 2021, reported achieving her financial goals with continuous corporate support, offering qualitative evidence of potential success. Similarly, Chad B. noted how owning a CryoFit franchise aligned with his passion for health and wellness, indicating a business model that can resonate with owner-operators. The independent FPI Score for Cryofit is 49, categorized as "Fair," providing an objective, albeit general, performance indicator from an external database. This score, combined with strong market growth projections and positive franchisee feedback, suggests that while specific financial disclosures are absent, the underlying market conditions and operational support could support a viable business. The growth trajectory of CryoFit, now bioworX, reflects a strategic evolution aimed at capitalizing on the expanding wellness market, albeit with a measured pace compared to initial aggressive projections. CryoFit initiated its franchising efforts in 2017. From its founding in 2014, the brand expanded to 11 locations by February 2023. While the founders had set ambitious targets in 2015 to reach 50 locations within two years and 250 within five years, these specific unit count goals were not met. However, the rebranding to bioworX has coincided with further expansion, with the new entity now operating 14 locations nationwide, demonstrating a net increase in units and a renewed focus on growth. The specific "Cryofit" brand name, as per independent database records, indicates 2 franchised units, reflecting a particular snapshot of its legacy operations. The most significant recent corporate development is the comprehensive rebranding to "bioworX: Essentials for Life," which represents a fundamental shift from a singular wellness service provider to a holistic brand offering an expanded suite of services. This transformation involves the incorporation of twelve unique modalities, significantly broadening its offerings beyond the core services of whole-body cryotherapy, IV drip infusions, infrared saunas, injectable vitamins, and compression boots. This expansion is strategically designed to lower inflammation and improve circulation, positioning bioworX as a leader in supporting the body's natural healing processes and optimizing performance. Leadership changes accompany this rebranding, with co-founder Brian Balli now serving as the President & Co-Founder of bioworX, indicating a continuity of founding vision within the new strategic direction. The competitive moat for bioworX is built upon this integrative approach, offering a diverse portfolio of science-based wellness solutions that cater to a wide range of client needs, from fitness enthusiasts and athletes seeking recovery to individuals focused on general health and well-being. The company's focus on an integrative approach with multiple modalities provides a distinct advantage over single-service providers. Furthermore, its SBA-approved franchise status enhances its appeal to prospective owners by facilitating access to financing. The brand is actively adapting to current market conditions by capitalizing on the booming $4.5 trillion global wellness industry and responding to consumer trends that favor non-invasive treatments and comprehensive health solutions. This strategic evolution, marked by rebranding and service expansion, is designed to create a resilient and competitive franchise model. The ideal franchisee for a bioworX (formerly CryoFit) center is someone deeply aligned with the brand's mission to provide comprehensive, science-based wellness solutions, although specific prior experience is not explicitly mandated. While the brand prefers franchisees to be actively involved in their store's operations, indicating a leaning towards an owner-operator model, it is not a mandatory requirement, which allows for flexibility for those with strong management teams or multi-unit aspirations. Testimonials from existing franchisees, such as Chad B., highlight a lifelong passion for health and wellness and a desire to help clients find suitable wellness protocols, suggesting that a genuine interest in the industry and its benefits is a key attribute. The availability of multi-unit development opportunities signals that the brand is seeking ambitious entrepreneurs capable of scaling operations across multiple locations. Geographically, CryoFit's initial footprint included locations primarily in Texas and some in Wisconsin, demonstrating success in diverse markets; the rebranded bioworX has expanded to 14 locations nationwide, indicating a broader territorial focus and potential for growth across the country. The company supports new owners by assisting with location criteria and connecting them with commercial real estate brokers in their area, suggesting a strategic approach to market penetration rather than a passive territory assignment. While the specific timeline from signing to opening, franchise agreement term length, or details on transfer and resale considerations are not explicitly provided, the robust support structure for site selection, construction, and design implies a guided and structured launch process for new franchisees. The significant liquid capital requirement of $250,000 or $257,000 and a net-worth requirement of $350,000 further define the ideal candidate as a financially secure individual or group capable of making a substantial Cryofit franchise investment. For franchise investors contemplating an entry into the high-growth wellness sector, bioworX, formerly CryoFit, presents a compelling franchise opportunity that warrants serious due diligence. The brand's strategic rebranding to "bioworX: Essentials for Life" and its expansion to twelve unique, science-backed modalities position it as a forward-thinking player in the $4.5 trillion global wellness industry. This evolution from a pioneer in wellness services to a holistic provider of solutions for lowering inflammation and improving circulation aligns perfectly with surging consumer demand for non-invasive treatments and comprehensive health optimization. The robust market projections for both cryotherapy (projected to reach $325.3 million by 2030 at a 7.8% CAGR) and the broader outpatient care market (expected to hit $157.5 billion by 2034 with a 12.5% CAGR) underscore a fertile environment for growth. While specific Item 19 financial performance data is not disclosed, the brand's growth from 11 locations to 14 nationwide under the new identity, coupled with positive franchisee testimonials and an independent FPI Score of 49 (Fair), suggests a viable operational model supported by comprehensive training and premier marketing support. This opportunity is for entrepreneurs ready to commit significant capital, with a Cryofit franchise cost ranging from $299,050 to $446,700 for bioworX, and meeting liquid capital requirements of $250,000 or $257,000 and a net worth of $350,000. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools. Explore the complete Cryofit franchise profile on PeerSense to access the full suite of independent franchise intelligence data.

Hydrate Iv Bar

All Other Outpatient Care Centers

66

Strong

For discerning investors navigating the rapidly expanding health and wellness sector, the critical question often revolves around identifying a franchise opportunity that is not only robust but also poised for sustained growth amidst evolving consumer demands. The challenge lies in distinguishing truly scalable models from fleeting trends, especially in a market valued globally at $4 trillion, where the intravenous (IV) hydration therapy segment alone is projected to grow from USD 2.83 billion in 2025 to USD 5.66 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 9.2% from 2026 to 2033. Hydrate IV Bar, a prominent IV therapy spa franchise, presents itself as a compelling solution within this dynamic landscape, offering a comprehensive business model that has demonstrated significant traction since its inception. Founded in 2016 in Denver, Colorado, by Katie Gillberg, also known as Katie Wafer-Gillberg or Katie Wafer, the company maintains its headquarters in Denver, Colorado, with Katie Wafer-Gillberg serving as the Founder and CEO. The leadership team is further strengthened by Amy Dickerson as Managing Partner and Eric Osborne overseeing Franchise Development. This strategic leadership has guided the brand's rapid expansion, transitioning from four corporate spas established across the Denver metro area by late 2020 to offering franchise opportunities in the same year, with the first franchise location opening in September 2020. The Hydrate IV Bar franchise has since scaled impressively, reporting 10 open locations across Arizona, Colorado, and Texas by August 2023, alongside an additional seven in development. By January 27, 2025, the brand had reached 18 locations nationwide, marked by the inauguration of its Cypress, Texas spa, and further accelerated to 26 locations across five states by February 27, 2026. An earlier report from December 4, 2025, indicated 25 open locations with ambitious plans for 25 more, targeting a total of 100 units. This rapid growth trajectory, coupled with a track record of serving over 90,000 clients, selling more than 10,000 memberships, and garnering over 15,000 five-star reviews, firmly establishes Hydrate IV Bar as a significant and growing entity solely within the United States market. While some external databases report a snapshot of 5 total units, 6 franchised units, and 0 company-owned units, the detailed and progressive growth timeline provided directly by the company’s updates paints a picture of aggressive, successful expansion, positioning the Hydrate IV Bar franchise as a key player in a high-demand industry. The intravenous hydration therapy market is not merely growing; it is undergoing a profound transformation, evolving from a niche recovery treatment into a mainstream wellness category, a shift driven by significant consumer and healthcare trends. The global health and wellness industry itself is a colossal $4 trillion market, providing a vast total addressable market for the Hydrate IV Bar franchise. Within this broader context, the global intravenous hydration therapy market was valued at USD 2.83 billion in 2025 and is projected to reach USD 5.66 billion by 2033, demonstrating a robust Compound Annual Growth Rate (CAGR) of 9.2% from 2026 to 2033. Other projections further underscore this expansion, estimating the market at USD 2.94 billion in 2025, expanding to USD 4.60 billion by 2030 with an 8.9% CAGR, and from USD 2.71 billion in 2024 to USD 5.84 billion by 2034 with a CAGR of 7.98% from 2025 to 2034. These figures highlight a compelling secular tailwind benefiting the Hydrate IV Bar franchise, as consumers increasingly incorporate monthly drip appointments as a routine investment in their well-being. Key drivers for this sustained growth include the rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, autoimmune conditions, and cancer, alongside the increasing popularity of wellness and beauty treatments. Furthermore, the growing availability and ease of use of IV hydration therapy clinics directly contribute to market expansion. North America has consistently dominated this market, holding a substantial 47.5% share in 2025 and 47% in 2024, with the U.S. market alone expected to reach USD 2.43 billion by 2034 from USD 1.11 billion in 2024, growing at an 8.15% CAGR. This regional dominance, coupled with the fact that in-clinic medical spas held a significant 46.3% share of the market in 2024, provides a strong foundation for the Hydrate IV Bar franchise model. The market is characterized by diverse service segments, with energy boosters holding the largest market share at 26.36% in 2025 and 27% in 2024, while the skin care segment is projected to experience the fastest growth. Vitamin cocktails accounted for 44.6% of the IV hydration therapy market share in 2024, and NAD+ protocols are showing significant advancement with a 15.2% CAGR through 2030, indicating a dynamic and segmented industry ripe for specialized franchise investment. Investing in a Hydrate IV Bar franchise requires a clear understanding of the financial commitments, which position it as a mid-tier investment opportunity within the wellness sector, balancing accessibility with significant growth potential. The initial franchise fee for a Hydrate IV Bar is $45,000, representing the entry cost for securing the rights to operate under the established brand and system. The total initial investment required to open a Hydrate IV Bar franchise ranges from $238,000 to $454,000, a range that reflects various expenses including construction, necessary equipment, initial inventory, and operating costs. This current investment range has evolved from earlier figures, which indicated a total investment of $206,100 to $412,250 in August 2023, and an even lower range of $150,000–$200,000 in August 2020, demonstrating the brand's growth and increasing operational sophistication. The spread within the total investment is primarily driven by factors such as the specific geographic location, the extent of build-out or renovation required for a typical 900 to 1200 square foot spa, and initial inventory levels. To qualify for a Hydrate IV Bar franchise opportunity, prospective franchisees are required to have a minimum of $125,000 in liquid capital, ensuring sufficient immediate funds for startup and initial operations. Additionally, a minimum net worth of $500,000 is required, underscoring the brand’s preference for financially stable investors. Working capital, estimated between $60,000 and $90,000, is also factored into the initial investment to cover additional funds needed for the first three months of operation, providing a crucial buffer during the launch phase. Beyond the initial investment, ongoing fees include an 8% royalty rate on gross revenue, which supports the continued development and maintenance of the Hydrate IV Bar system and brand. Franchisees also contribute 2% of their gross revenue to a dedicated brand marketing fund, which finances national marketing initiatives aimed at enhancing brand visibility and driving customer traffic across the entire network. While specific technology or marketing fees beyond the ad fund are not detailed, these ongoing contributions are standard in the franchise model, ensuring collective brand strength. For those requiring financial assistance, third-party financing options are available, and Hydrate IV Bar demonstrates its commitment to supporting military veterans by offering a veteran discount of $5,000 off the initial franchise fee, making the Hydrate IV Bar franchise more accessible to a valuable segment of the population. The operational model of a Hydrate IV Bar franchise is meticulously designed to ensure consistency, compliance, and client satisfaction, underpinned by robust corporate support and a clear operational framework. Franchisees are engaged in daily operations that focus on delivering a range of IV therapy services, managing monthly memberships, service packages, and shot passes, which collectively contribute to the brand's recurring revenue streams. The typical Hydrate IV Bar location occupies between 900 and 1200 square feet, providing an efficient footprint for its specialized services. Staffing requirements are streamlined through a critical partnership with Guardian Medical Direction, which provides standardized medical oversight, telemedicine clearance workflows, and state-by-state regulatory evaluation, thereby simplifying the clinical management aspect for franchisees. This partnership establishes comprehensive clinical protocols, supports new market entry by navigating local regulations, and ensures that all franchise locations operate within clearly defined regulatory and scope-of-practice standards. The telemedicine model is particularly advantageous, facilitating faster clearances and same-day service access for clients, while also empowering nurses in single-clinician environments by enhancing safety and reducing clinical decision-making ambiguity. For franchisees, the franchisor also offers resources to assist in finding a qualified Medical Director for their spa if needed, further alleviating a significant operational concern. Comprehensive training programs are provided to all new franchise owners, with estimated expenses for this training ranging between $4,500 and $8,500, ensuring they are fully equipped to manage their Hydrate IV Bar franchise effectively. Beyond initial training, franchisees receive ongoing backing from the corporate team's experienced professionals, covering various aspects of business management and operations. A crucial element of the Hydrate IV Bar franchise offering is territory protection, which grants franchisees a specific geographical area where no other Hydrate IV Bar franchises can be established, thereby helping to build and maintain a strong customer base without direct competition from other brand locations. While specific multi-unit requirements are not explicitly stated, the brand’s ambitious growth plans towards 100 units suggest a favorable environment for multi-unit operators. The model is structured to support dedicated owner-operators, though the robust medical and operational support systems could potentially facilitate a semi-absentee ownership model for experienced business managers. For prospective investors evaluating the financial viability of a Hydrate IV Bar franchise, the brand provides transparent performance data within its Franchise Disclosure Document. Item 19 of the Hydrate IV Bar FDD reports an average gross sales of $712,422, with top-performing units achieving a high of $1,650,955. These figures offer a clear benchmark for potential revenue generation, though individual results are acknowledged to vary based on crucial factors such as specific location, market dynamics, and the operational effectiveness of the ownership team. A significant portion of the brand's revenue, over 40%, is derived from memberships, establishing a predictable and recurring revenue base that strengthens as client community engagement deepens. This membership model is highlighted as a key differentiator within the wellness franchise space, providing a stable foundation for financial performance and contributing to long-term client retention. The company further suggests that franchisees can achieve up to 43% EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), indicating strong profitability potential after operational expenses but before accounting for capital structure and non-cash items. The business model is strategically structured around these monthly memberships, alongside service packages and shot passes, all designed to foster recurring revenue streams and enhance customer loyalty. When considering the initial investment range of $238,000 to $454,000, an average gross sales of $712,422 and a potential EBITDA of up to 43% suggest a compelling return on investment and a relatively favorable payback period, although specific payback period analyses would require deeper financial modeling based on individual unit performance and operating costs. The consistent growth trajectory of the Hydrate IV Bar franchise, from 4 corporate spas in late 2020 to 26 locations by February 2026, further validates the underlying unit-level economics and market acceptance, signaling a brand with a proven ability to scale profitably. The growth trajectory of the Hydrate IV Bar franchise illustrates a deliberate and successful expansion strategy within the burgeoning IV therapy market. After establishing its initial success with four corporate spas across the Denver metro area by late 2020, the company strategically began offering franchise opportunities, opening its first franchise location in September 2020. This foundational period quickly led to significant expansion, with the brand reporting 10 open locations across Arizona, Colorado, and Texas by August 2023, accompanied by an additional seven units in various stages of development. The acceleration continued, reaching 18 locations nationwide by January 27, 2025, a milestone marked by the opening of its Cypress, Texas spa. More recently, as of February 27, 2026, the Hydrate IV Bar franchise operates 26 locations across five states, representing a net increase of 16 units from August 2023 to February 2026, averaging approximately 6-7 new units per year. This rapid growth aligns with an ambitious earlier report from December 4, 2025, which indicated 25 open locations with plans for 25 more on the way, aiming to achieve a total of 100 units, demonstrating a clear vision for market dominance. The brand’s competitive moat is built upon several key advantages, starting with significant brand recognition and customer loyalty, evidenced by over 90,000 clients served, more than 10,000 memberships sold, and an impressive collection of over 15,000 five-star reviews. A proprietary and highly effective operational model, particularly its membership-driven revenue structure accounting for over 40% of sales, provides a stable recurring income base. Furthermore, the strategic partnership with Guardian Medical Direction offers a robust infrastructure for standardized medical oversight, efficient telemedicine clearance workflows, and comprehensive state-by-state regulatory evaluation. This medical compliance and support system is a significant differentiator, enhancing safety, reducing clinical decision-making ambiguity for nurses, and facilitating faster client clearances. By leveraging its proven business model and strong operational support, the Hydrate IV Bar franchise is effectively adapting to current market conditions, capitalizing on the mainstream adoption of IV therapy and the growing consumer demand for convenient, personalized wellness solutions. The ideal Hydrate IV Bar franchise candidate is envisioned as an individual with a strong business acumen and the financial capacity to capitalize on a high-growth wellness opportunity. While specific industry experience is not explicitly mandated, the required minimum liquid capital of $125,000 and a net worth of $500,000 indicate a preference for financially stable and seasoned investors capable of managing a significant business venture. The comprehensive training and support provided by the corporate team, coupled with the specialized medical oversight from Guardian Medical Direction, are designed to equip franchisees from diverse professional backgrounds for success. Although the franchise disclosure does not explicitly outline multi-unit ownership requirements, the brand's ambitious goal of reaching 100 units strongly suggests that multi-unit operators are actively sought and encouraged, offering significant growth potential for ambitious franchisees. The Hydrate IV Bar franchise is strategically expanding its footprint, currently operating in Colorado, Arizona, Texas, and Utah. The company is actively seeking qualified franchise candidates and offering locations in a wide range of additional states, including Alabama, Arkansas, Connecticut, Iowa, Kansas, Kentucky, Mississippi, Missouri, Montana, Nebraska, Nevada, New Jersey, Ohio, Oklahoma, Pennsylvania, and Wyoming. Furthermore, the brand is particularly focused on growth in "hot markets" identified for high demand and favorable market conditions, such as Arizona, Colorado, Florida, Georgia, Idaho, North Carolina, South Carolina, Tennessee, Texas, and Utah. Inquiries are currently being accepted from Florida, Georgia, Idaho, Indiana, Michigan, Tennessee, Texas, Utah, and Wisconsin, indicating specific areas of immediate expansion interest. While franchise opportunities are available throughout the United States, California is currently pending for availability, and North Dakota, South Dakota, and Hawaii are noted as exceptions, defining the current geographic scope for new Hydrate IV Bar franchise development. For investors seeking to enter the burgeoning health and wellness sector with a proven model, the Hydrate IV Bar franchise presents a compelling investment thesis. This franchise opportunity is anchored in a substantial and rapidly expanding industry, with the global health and wellness market valued at $4 trillion and the IV hydration therapy segment alone projected to reach USD 5.66 billion by 2033. The brand demonstrates a strong operational track record, evidenced by its growth from 4 corporate spas to 26 locations across five states by February 2026, and a clear strategic vision to achieve 100 units. Unit-level economics are robust, with Item 19 of the FDD reporting an average gross sales of $712,422 and a high of $1,650,955, alongside the potential for franchisees to achieve up to 43% EBITDA. The unique membership-driven revenue model, accounting for over 40% of sales, provides a stable, recurring income stream, differentiating the Hydrate IV Bar franchise in a competitive market. Furthermore, comprehensive training and ongoing corporate support, including the critical partnership with Guardian Medical Direction for medical oversight

Prevail Heart Clinics Of Ameri

All Other Outpatient Care Centers

44

Fair

The question facing any serious franchise investor considering the outpatient healthcare space is not simply whether the industry is growing — it demonstrably is, with the U.S. outpatient care market surpassing $800 billion in annual expenditure — but whether a specific brand within that space has the clinical model, operational infrastructure, and market positioning to generate durable returns at the unit level. Prevail Heart Clinics Of Ameri represents a franchise opportunity in one of the most structurally compelling healthcare subspecialties in the modern economy: cardiovascular outpatient care. Heart disease remains the leading cause of death in the United States, accounting for approximately 697,000 deaths annually according to the Centers for Disease Control, and the clinical infrastructure required to serve the roughly 128 million Americans living with some form of cardiovascular disease or risk factor remains dramatically underdeveloped in the outpatient, non-hospital setting. The Prevail Heart Clinics Of Ameri franchise operates within the FDD category of All Other Outpatient Care Centers, a classification that encompasses specialty clinical services delivered outside of traditional hospital systems — a segment experiencing accelerating demand as payors, patients, and employers increasingly push care toward lower-cost, higher-convenience outpatient environments. With a current network of 1 franchised unit, Prevail Heart Clinics Of Ameri is an early-stage franchise concept, which means investors evaluating this brand are not buying into a mature, saturated system — they are assessing ground-floor positioning in a category where the secular tailwinds are among the strongest in all of healthcare franchising. This analysis from PeerSense is independent research, not marketing material from the franchisor, and is designed to give serious investors the unvarnished data and context needed to make an informed capital allocation decision. The outpatient care center industry in the United States is one of the fastest-growing segments within the broader $4.5 trillion U.S. healthcare economy. The outpatient surgery and specialty clinic market alone is projected to reach $93.2 billion by 2027, growing at a compound annual growth rate of approximately 5.8%, driven by structural shifts in how insurers reimburse care, how patients seek convenience, and how providers are incentivized to move procedures out of high-overhead hospital settings. Cardiovascular care is particularly positioned for outpatient migration: the American College of Cardiology estimates that more than 80% of cardiology visits and a growing share of diagnostic and monitoring procedures can be appropriately delivered in outpatient settings, yet the majority of cardiovascular care in the U.S. still flows through hospital-affiliated systems that carry significantly higher per-encounter costs. Consumer trends are accelerating this shift — an aging Baby Boomer population (approximately 73 million Americans born between 1946 and 1964) is the primary driver of cardiovascular service demand, with adults over 65 utilizing cardiology services at nearly three times the rate of the general population. Simultaneously, telehealth integration and remote cardiac monitoring technologies have expanded the care scope that outpatient facilities can deliver profitably, transforming what was once a referral-only specialty into a direct-access care model with strong patient acquisition economics. The competitive landscape for cardiovascular outpatient franchises remains exceptionally fragmented — unlike urgent care or physical therapy, where national franchise chains with hundreds of locations have consolidated significant market share, cardiovascular specialty outpatient care has seen minimal franchised brand development, creating an open field for concepts with clinical credibility and operational scalability. The Prevail Heart Clinics Of Ameri franchise investment profile is a subject that warrants careful and thorough due diligence precisely because the brand is at an early stage of franchise development. For context, outpatient healthcare franchise concepts generally carry initial franchise fees ranging from $25,000 to $75,000, depending on the clinical complexity of the service model, the depth of proprietary protocols provided, and the exclusivity of the territorial grant. Total investment ranges for outpatient specialty clinic franchises vary considerably based on whether the concept involves a full clinical build-out with diagnostic equipment, a leased medical office conversion, or a partnership model with an existing healthcare facility — with lower-end configurations often starting around $150,000 to $250,000 for conversion or licensing models, and full de novo clinical build-outs for specialty care potentially reaching $500,000 to $1.2 million when medical equipment, leasehold improvements, working capital, and pre-opening expenses are fully capitalized. Cardiovascular diagnostic equipment — including echocardiography systems, EKG monitoring infrastructure, stress testing equipment, and remote cardiac monitoring technology — represents a significant capital line item that differentiates cardiovascular clinic investment from lighter-touch outpatient concepts. Prospective Prevail Heart Clinics Of Ameri investors should engage directly with the franchisor's Franchise Disclosure Document to obtain the current Item 7 investment table, which will enumerate all required and estimated pre-opening costs with precision. SBA 7(a) and SBA 504 loan programs have historically been accessible to healthcare franchise concepts, particularly those with tangible asset bases including medical equipment, which can serve as collateral in structured financing arrangements. The FPI Score for Prevail Heart Clinics Of Ameri currently stands at 44, which PeerSense categorizes as Fair — a score that reflects the brand's early-stage development and limited system-wide performance history rather than a negative indicator of the underlying business model. Daily operations within a Prevail Heart Clinics Of Ameri franchise unit center on the delivery of cardiovascular outpatient services, which typically encompass a combination of diagnostic testing, patient monitoring, preventive care consultations, and coordination with referring physicians and cardiologists. The labor model for a cardiovascular specialty outpatient clinic is clinically intensive by nature — staffing typically includes a combination of licensed cardiovascular technicians, registered nurses with cardiac specialty training, medical assistants, and administrative personnel responsible for insurance verification, prior authorizations, and scheduling, all of which operate under physician oversight either on-site or through a medical director arrangement compliant with state corporate practice of medicine laws. The regulatory complexity of healthcare franchising — including compliance with HIPAA, state licensure requirements, Medicare and Medicaid provider enrollment, and Joint Commission accreditation standards — means that the training and onboarding infrastructure provided by a franchisor in this category carries exceptional importance for franchisee success. Comprehensive training programs for outpatient healthcare franchise concepts typically span four to eight weeks and combine classroom instruction in clinical protocols, compliance frameworks, billing and coding best practices, and operational systems with hands-on clinical observation and site preparation support. Ongoing support in healthcare franchising should include field consultation visits by clinical compliance experts, access to proprietary electronic health record and practice management platforms, marketing support for physician referral network development, and guidance on payor contracting — all areas where a franchisor with deep cardiovascular care experience can provide meaningful operational leverage to franchisees navigating a complex regulatory and reimbursement environment. Territory structure in outpatient healthcare franchising is typically defined by population thresholds, ZIP code clusters, or county boundaries, with exclusive or protected territories granted to franchisees who meet development commitments. Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for Prevail Heart Clinics Of Ameri, which means prospective investors must rely on industry benchmarks and category-level data to build their financial models during the due diligence process. This is not an uncommon situation for early-stage franchise concepts — the Federal Trade Commission's franchise rule does not require Item 19 disclosure, and many emerging brands with limited operating history opt not to publish financial performance representations until they have a statistically meaningful number of units generating auditable performance data. For context, outpatient specialty care clinics in the United States generate average annual revenues that vary widely by specialty and business model: urgent care centers average approximately $1.1 million to $2.3 million in annual revenue per location, physical therapy outpatient clinics average between $700,000 and $1.5 million, and cardiovascular diagnostic centers — particularly those with strong payor contracting and physician referral relationships — can generate revenues in the range of $800,000 to $3.5 million annually depending on procedure volume, payor mix, and service line breadth. Operating margins in outpatient healthcare generally range from 8% to 22% at the clinic level, with higher margins achieved in concepts with strong proprietary diagnostic protocols, efficient staffing ratios, and favorable reimbursement contracts with commercial insurers. The cardiovascular outpatient category benefits from Medicare and commercial insurer reimbursement for a broad range of diagnostic and monitoring services, providing a revenue base with relatively durable demand characteristics compared to elective or consumer-pay healthcare categories. Investors conducting due diligence on Prevail Heart Clinics Of Ameri should request audited or reviewed financial statements from any operating franchised units as part of the franchise disclosure process, and should engage an independent healthcare financial consultant familiar with physician practice management and outpatient clinic economics to validate revenue and margin assumptions. The growth trajectory of Prevail Heart Clinics Of Ameri is, at present, defined by its position as a single-unit franchised system — a stage that every multi-hundred-unit healthcare franchise concept once occupied before scaling. The significance of early entry into a cardiovascular outpatient franchise cannot be overstated in the context of market timing: the U.S. cardiovascular disease burden is projected to increase substantially over the next two decades as the population ages, with the American Heart Association estimating that by 2035, more than 45% of the U.S. population will have some form of cardiovascular disease, generating an estimated $1.1 trillion in direct and indirect costs annually. The competitive moat available to an early franchisee in a cardiovascular outpatient brand is primarily geographic — establishing a dominant clinical presence in a defined metropolitan or suburban market before competing outpatient cardiovascular concepts enter creates patient and physician referral relationships that are structurally durable. The broader healthcare franchise sector has demonstrated robust expansion capacity: urgent care franchise networks grew from fewer than 200 locations in 2000 to over 10,000 locations by 2022, a trajectory that cardiovascular outpatient care — currently fragmented among independent practices and hospital-affiliated outpatient departments — has not yet experienced but is structurally positioned to follow. Digital health integration, including remote patient monitoring platforms, AI-assisted cardiac screening tools, and telehealth follow-up protocols, represents a significant technology investment opportunity for cardiovascular franchise concepts that can differentiate through data-driven care delivery. Brands that establish proprietary clinical technology ecosystems early in their development cycle build switching costs and operational differentiation that are extremely difficult for later entrants to replicate. The ideal candidate for a Prevail Heart Clinics Of Ameri franchise opportunity occupies a specific intersection of healthcare operational experience, capital capacity, and community relationship-building capability. Given the clinical nature of cardiovascular outpatient care, the strongest franchisee profiles typically include individuals with backgrounds in healthcare administration, physician practice management, hospital operations, or healthcare services entrepreneurship — rather than clinical practitioners themselves, since most state corporate practice of medicine laws require physician-owned or physician-supervised entities for clinical service delivery. Multi-unit development potential in an early-stage franchise system is particularly significant, as franchisees who secure territorial rights in high-population markets during the brand's formative years often capture the most valuable and defensible footprints — a dynamic well-documented in the growth histories of urgent care, physical therapy, and behavioral health franchise systems. Geographic markets with high concentrations of adults over 55, elevated rates of cardiovascular risk factors including diabetes and hypertension, and underserved outpatient cardiology infrastructure represent the highest-potential territories for a cardiovascular specialty franchise concept. Timeline from franchise signing to clinical opening for an outpatient healthcare concept is typically longer than for food and beverage or retail franchises, often ranging from six to eighteen months depending on the complexity of the build-out, state licensure timelines, Medicare provider enrollment processing, and payor credentialing — all of which investors should model conservatively in their cash flow projections. The franchise agreement term length and renewal structure are critical negotiation and review points for healthcare franchise investors, given the capital intensity of the build-out and the long-term nature of the clinical relationships being developed. Synthesizing the available data and industry context, the Prevail Heart Clinics Of Ameri franchise opportunity warrants serious due diligence from investors with both the financial capacity and operational background to operate in the healthcare services sector. The investment thesis rests on three structural pillars: the undeniable demographic demand trajectory for cardiovascular care services in an aging U.S. population, the accelerating shift of cardiovascular diagnostics and monitoring from hospital-based to outpatient settings driven by payor economics and patient preference, and the early-stage positioning of a franchise concept in a category that has not yet experienced the consolidation and brand standardization that defines mature healthcare franchise sectors like urgent care. The FPI Score of 44, categorized as Fair by PeerSense's independent scoring methodology, appropriately reflects the limited operating history and single-unit scale of the current system — and investors should weight that score in the context of what it represents: an early-stage franchise in a high-growth healthcare category, not a mature system with established unit-level performance benchmarks. The absence of Item 19 financial disclosure in the current FDD is a factor that should motivate investors to conduct especially rigorous independent financial modeling using industry benchmarks, operator interviews, and healthcare financial advisory support before committing capital. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark Prevail Heart Clinics Of Ameri against comparable outpatient healthcare franchise concepts across every relevant investment dimension. The cardiovascular outpatient care market is one of the most consequential healthcare investment themes of the next decade, and understanding exactly where Prevail Heart Clinics Of Ameri sits within that landscape requires the kind of independent, data-driven analysis that no franchisor's sales materials can provide. Explore the complete Prevail Heart Clinics Of Ameri franchise profile on PeerSense to access the full suite of independent franchise intelligence data.

Sarahcare

All Other Outpatient Care Centers

22

Limited

Every year, more than 11,000 Americans turn 65, a demographic wave that is reshaping the healthcare landscape and creating one of the most durable franchise investment opportunities of the next two decades. For adult children watching a parent decline after a stroke, or for family caregivers stretched between a full-time job and the demands of aging loved ones, the gap between inadequate options — expensive residential memory care at $5,000-plus per month, or unreliable home aides — and genuinely enriching daily care has been a painful reality for millions of families. SarahCare was built specifically to close that gap. Founded in 1985 by Dr. Merle Griff, a psychologist and experienced gerontologist based in Canton, Ohio, the company emerged not from a boardroom strategy session but from a deeply personal crisis: Dr. Griff could not find adequate care for her own mother following a severe stroke, and her clinical practice confirmed this was not an isolated problem. The original concept was called S.A.R.A.H. — Senior Adult Recreation and Health — and the first center opened in Canton, which remains the corporate headquarters today. SarahCare began extending its model through franchising, and as of 2024 operates 21 total units across 13 U.S. states, including Connecticut, Florida, Georgia, Idaho, Indiana, Massachusetts, Michigan, New Jersey, North Carolina, Ohio, Pennsylvania, and Texas. The philosophy underpinning every center is called "The SarahCare Way," a holistic care model addressing the physical, mental, and spiritual needs of participants while providing meaningful respite for family caregivers. SarahCare holds CARF accreditation — Commission on Accreditation of Rehabilitation Facilities — a designation held by only 110 of the approximately 4,500 adult day centers operating in the United States, placing SarahCare in the top 2.4% of providers nationally by quality certification. This analysis is produced by PeerSense as independent franchise research, not promotional content commissioned by the brand. The total addressable market for outpatient care centers, the NAICS 6214 category in which SarahCare operates, is approximately $230 billion in the United States, growing at a compound annual growth rate of 5.8%. Globally, the outpatient care market was valued at approximately $48.5 billion in 2024 and is projected to reach $157.5 billion by 2034, representing a CAGR of roughly 12.5% between 2025 and 2034. A parallel estimate pegs the global market at $47.7 billion in 2023 with an anticipated trajectory toward $133.3 billion by 2032, implying a 12.1% CAGR over that nine-year period. Several powerful demographic and policy forces are converging to accelerate demand specifically for adult day health services. The U.S. Census Bureau projects that all Baby Boomers will be 65 or older by 2030, adding tens of millions of elderly Americans to the pool of potential adult day service participants within this decade alone. Chronic illness is a structural driver: the increasing prevalence of diabetes, cardiovascular disease, and neurological conditions means that more seniors require daily health monitoring, medication management, and therapeutic programming rather than full-time residential placement. On the policy side, new Medicare Advantage plans now permit coverage of adult day services, a reimbursement shift that dramatically expands the financially accessible client base for centers like SarahCare. The cost efficiency argument is compelling: SarahCare's per-day model is demonstrably less expensive than daily home care or residential assisted living, positioning the service as the economically rational choice for families navigating senior care decisions. The adult day service sector remains fragmented — SarahCare describes itself as the only company in the country proven successful over time in offering adult day care franchises, a competitive positioning claim that reflects the absence of scaled national franchise competitors in this specific niche. The SarahCare franchise investment spans a range driven by factors including real estate selection, facility buildout versus conversion, local construction costs, and market geography. The total investment range documented across multiple Franchise Disclosure Document filings sits between approximately $379,690 and $849,700, with the 2020 FDD specifically citing $379,690 to $778,700 as the estimated range, of which $35,000 to $54,900 is paid directly to the franchisor or an affiliate. For context, the initial franchise fee is $34,900 at the minimum, with veterans receiving a 50% discount that reduces the fee to $31,410 — a meaningful incentive in a sector where military backgrounds often correlate with the discipline and leadership qualities that drive successful center operations. Prospective franchisees should plan for liquid capital of at least $100,000 to $150,000 depending on the source consulted, and a minimum net worth of $250,000 is required to qualify. Working capital alone is estimated between $127,920 and $162,400, reflecting the reality that adult day health centers carry meaningful operational costs — licensed nursing staff, facility overhead, programming materials, and transportation coordination — before reaching stabilized enrollment. The royalty fee structure ranges from 2.0% to 7.0% of gross sales, with a 5.0% figure cited in the 2017 FDD data as the operative rate at that time. One data source references an ad fund fee structure of 8.0% in the 2017 FDD context, which investors should clarify with current FDD documentation during due diligence. The SarahCare franchise cost, when assessed against the $230 billion TAM and the CARF-accredited quality positioning, places it in the accessible-to-mid-tier range for healthcare franchise investments, particularly compared to skilled nursing or residential memory care facility investments that can require millions in capital before opening day. SBA financing eligibility is a relevant consideration for prospective investors, and veterans should specifically inquire about the 50% franchise fee discount during initial discovery conversations. The SarahCare operating model is structured around a Monday-through-Friday schedule, typically running from 7:00 a.m. to 6:00 p.m., which is a significant structural advantage for franchisee lifestyle and staffing logistics — there are no weekend, holiday, or evening operations to manage. This schedule eliminates the burnout-inducing complexity of seven-day staffing rotations that plague other healthcare service models and allows franchisees to maintain predictable operational rhythms. Centers are staffed with licensed nurses who manage chronic health conditions and medication administration, meaning the clinical dimension of the operation is handled by credentialed professionals rather than by the franchisee owner, who is not required to have any prior healthcare background or clinical experience. SarahCare actively seeks owners and investors with business or sales backgrounds who are motivated by the mission of helping families keep seniors at home and age in place — the ideal profile is a community-oriented leader with strong communication skills, not a healthcare administrator. New franchisees complete a two-week training program conducted at SarahCare's corporate headquarters in Canton, Ohio, covering operational systems, staffing models, programming philosophy, regulatory compliance, and the principles of The SarahCare Way. Beyond initial training, franchisees receive ongoing field visits and telephone support from professionals with extensive experience in adult day service center management, along with a detailed operations manual that codifies best practices across every dimension of center operation. The ongoing support structure includes monthly virtual meetings and bi-annual in-person meetings where owners and their representatives discuss new programs, service updates, and system-wide adaptations to evolving family needs. Territory structure provides franchisees with defined geographic zones, and the overall support architecture is designed to accompany owners from the initial discovery phase through on-site orientation training, center opening, and long-term operational maturity. Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document on file at the time of this analysis. This is a material fact that prospective SarahCare franchise investors must weigh carefully during due diligence, as the absence of Item 19 disclosure means the franchisor has chosen not to provide audited or compiled unit-level financial performance representations in the current FDD cycle. That said, publicly available data from prior FDD filings and third-party research provides meaningful financial context. The 2024 average unit revenue for a SarahCare franchise has been reported at $645,750, and one earnings analysis citing FDD-period data projects yearly gross sales of approximately $553,963 with estimated owner earnings in the range of $99,714 to $138,491 annually. The estimated payback period for a SarahCare franchise investment falls between 6.6 and 8.6 years based on these revenue and earnings projections, which is consistent with healthcare services franchises that carry higher upfront buildout costs but benefit from recurring, relationship-driven client enrollment and reimbursement-supported revenue streams. The spread between the low and high earnings estimates reflects the operational variability inherent in adult day health centers, where enrollment levels, local Medicaid and Medicare Advantage reimbursement rates, staffing costs, and facility lease terms all influence the bottom line. The working capital requirement of $127,920 to $162,400 signals that operators should anticipate a ramp period before reaching breakeven enrollment, a common characteristic of healthcare facilities that build census through referral relationships with hospitals, physicians, and social service agencies. Investors should request updated Item 19 disclosure from the current FDD during the formal discovery process and engage an independent franchise attorney and accountant to model unit economics against local market conditions before making a capital commitment. SarahCare's growth trajectory reflects the dual dynamics of a pioneer brand navigating a maturing franchise model within an accelerating market. The company began franchising around 2000, and the 2017 Franchise Disclosure Document recorded 23 franchised locations across the United States — the largest concentration being in the South, with 8 franchise locations in that region alone. As of 2024, the system counts 21 total units, a figure that reflects some attrition from the 2017 peak alongside continued new development. Three new franchise locations were planned for opening in the Summer and Fall of 2023 in South Augusta, Georgia; Encino Park, Texas; and Springfield, Massachusetts, representing active system expansion into the South, Southwest, and New England markets simultaneously. The company's competitive moat is built on several reinforcing elements: the 39-year operating history since 1985 provides institutional knowledge that cannot be replicated quickly; the CARF accreditation, held by only 110 of 4,500 U.S. adult day centers, creates a credentialing barrier that differentiates SarahCare from independent operators and lower-quality competitors; and the claim to be the only proven adult day care franchise system in the country creates a category-of-one positioning in franchise recruitment conversations. Dr. Merle Griff's continued leadership as Founder and CEO, combined with her authorship of a caregiving resource book that has extended the brand's thought leadership reach, reinforces institutional continuity at the executive level. On the technology and policy front, the adoption of new Medicare Advantage plan coverage for adult day services is a particularly significant tailwind, as it expands reimbursement access in ways that directly benefit census-building at established centers with the clinical credentialing — like CARF accreditation — that payers increasingly require. The ideal SarahCare franchisee is a business-oriented individual with demonstrated leadership experience, strong community relationship-building skills, and genuine personal motivation around senior care and family wellness — not a clinical background. SarahCare explicitly states that no prior healthcare experience is necessary for owners, making this franchise accessible to entrepreneurs from sales, management, real estate, finance, and other service-industry backgrounds who are drawn to mission-driven business ownership. Multi-unit ownership is a logical progression for operators who establish strong local referral networks and achieve stabilized enrollment in an initial center, given the relatively consistent operating model across geographies. The brand currently operates in 13 states, with active franchise opportunities documented in Connecticut, Florida, Georgia, Idaho, Indiana, Massachusetts, Michigan, New Jersey, North Carolina, Ohio, Pennsylvania, and Texas, suggesting geographic white space in the Midwest, Mountain West, and Pacific regions for ambitious multi-market developers. Centers operating Monday through Friday, 7 a.m. to 6 p.m., are compatible with a semi-absentee or owner-operator model once the management team and nursing staff are properly hired and trained, though most early-stage operators are advised to maintain active oversight through the enrollment ramp period. The timeline from signing a franchise agreement to opening a center reflects the complexity of healthcare facility permitting, state licensure, and facility build-out — prospective franchisees should model a 12-to-18-month development runway as a conservative planning assumption, though this varies significantly by state regulatory environment and real estate conditions. The SarahCare franchise opportunity sits at the intersection of one of the most powerful demographic megatrends of the next twenty years — the aging of the Baby Boomer generation — and a professionalized, CARF-accredited service model that has been operating and refining its approach since 1985. The $230 billion total addressable market for outpatient care centers, growing at 5.8% annually domestically and at a 12.5% CAGR globally through 2034, provides a structural tailwind that makes senior care franchise investment a compelling category-level thesis independent of any single brand. The SarahCare franchise investment, ranging from approximately $379,690 to $849,700 in total capital outlay, positions this opportunity in the accessible-to-mid-tier range for healthcare franchises, with a veteran discount on the initial franchise fee, an operations model that does not require clinical ownership experience, and a support infrastructure including two-week headquarters training, monthly virtual meetings, and bi-annual in-person conferences. The publicly reported average unit revenue of $645,750 and estimated annual owner earnings of $99,714 to $138,491 provide reference points for financial modeling, though investors must obtain and analyze the current FDD independently. PeerSense provides exclusive due diligence data including SBA lending history, FPI score breakdowns, location maps with Google ratings, FDD financial data comparisons, and side-by-side franchise comparison tools that allow investors to benchmark SarahCare against other senior care and outpatient health franchise opportunities across every financial and operational dimension. Explore the complete SarahCare franchise profile on PeerSense to access the full suite of independent franchise intelligence data and begin a rigorous, data-driven evaluation of this senior care franchise opportunity.

The Salt Room Nonexclusive

All Other Outpatient Care Centers

38

Fair

The question every serious franchise investor should ask before writing a check is deceptively simple: does this brand solve a real, recurring consumer problem at a scale the market will sustain? For The Salt Room Nonexclusive franchise, that question lands squarely inside one of wellness's most compelling emerging categories — halotherapy, or dry salt therapy, a practice rooted in centuries of European spa tradition and now experiencing explosive commercial adoption across North America. The Salt Room brand traces its origins through a network of licensed and independently operated locations inspired by The Salt Room founded by Ashley Steiner in Orlando, Florida, a founding story that sparked a collective ecosystem of 15 Salt Room locations currently operating across the United States. Individual operators like Dani Howard, Owner and CEO of The Salt Room Wesley Chapel licensed in 2017 and The Salt Room and Sauna in Citrus Park, Tampa licensed in 2022, exemplify the entrepreneurial energy behind this concept, while locations like The Salt Room in Woodbury, Minnesota, originally opened by Gloria WahrenBrock in 2013, demonstrate the brand's decade-plus consumer resonance. The Salt Room Tell City was acquired by Eric and Becca Martin and their family in 2022, further illustrating the owner-operator culture that defines this network. The Salt Room Nonexclusive franchise currently operates with one total franchised unit, classifying it as an early-stage or micro-scale franchise opportunity, a status that carries both meaningful risk and the kind of ground-floor positioning that appeals to investors who prefer entering markets before saturation. The global salt therapy market is projected to reach $5.8 billion by 2027, growing at a compound annual growth rate of 6.7%, and the category sits within the broader All Other Outpatient Care Centers industry, which carries a total addressable market of approximately $230 billion. For investors willing to do rigorous due diligence on a nascent franchise model in a high-growth wellness category, The Salt Room Nonexclusive franchise warrants careful, independent analysis — and this profile is designed to provide exactly that. The industry backdrop for The Salt Room Nonexclusive franchise investment is among the most favorable of any outpatient wellness category. The global outpatient care market was valued at approximately $47.7 billion in 2023 and is projected to reach $133.3 billion by 2032, representing a compound annual growth rate of 12.1% — nearly double the rate of the U.S. economy's baseline expansion. A separate projection places the global outpatient care market at $48.5 billion in 2024, growing to $157.5 billion by 2034 at a CAGR of 12.5%, with North America expected to dominate the forecast period. The private segment of outpatient care held over 50% of global revenue share in 2024, reinforcing that consumer-facing, privately operated wellness concepts like salt therapy are riding a structural tailwind rather than fighting against one. Within the halotherapy subcategory specifically, consumer demand is described by industry analysts as "skyrocketing," driven by a growing cultural shift toward natural, non-pharmaceutical approaches to respiratory health, stress reduction, and holistic self-care. The contrast between North American market penetration and European adoption is stark: throughout the United States and Canada, just over 2,000 facilities currently offer salt therapy services, while across European countries virtually every spa offers halotherapy as a primary service — a penetration gap that represents enormous runway for North American franchise operators. Key secular tailwinds benefiting The Salt Room Nonexclusive franchise include an aging population increasingly seeking preventative wellness solutions, rising consumer health consciousness post-pandemic, and a documented preference for convenient outpatient care experiences over traditional hospital or clinic settings. The broader Outpatient Care Centers industry category carries a CAGR of 5.8% on its own, and when overlaid with the halotherapy-specific CAGR of 6.7%, the compounding opportunity for well-positioned operators becomes clear. The China and North American markets are characterized as "virtually untapped" relative to European saturation, meaning investors entering now are doing so well ahead of mainstream institutional capital flows into this category. Evaluating The Salt Room Nonexclusive franchise cost requires working with the data that is available while being transparent about the structural characteristics of a nonexclusive licensing model. The Salt Room Nonexclusive framework operates differently from rigidly defined single-system franchises, which means the investment structure can vary meaningfully based on location specifics, renovation requirements, and equipment configuration. For comparative context within the salt therapy category, The Salt Suite, a defined U.S.-based salt therapy franchise system founded in 2011 and franchising since 2016 out of Winston-Salem, North Carolina, carries an initial franchise fee of approximately $42,000, a total initial investment range of $238,650 to $483,100, a royalty rate of 8.0% of gross sales, and an advertising fund contribution of 2% of gross sales, with a liquid capital requirement of $100,000 and working capital needs between $25,000 and $55,000. These figures provide the most reliable industry benchmark for what a salt therapy franchise investment of similar scale and category should cost to enter. For operations like Center of Salt Therapy, which holds two successful locations and a decade of experience in the category, equipment costs are fixed with quotes provided on request, while renovation and location-specific costs drive the total investment spread. The Salt Room Nonexclusive franchise, with its website hosted at thesaltroom.co.uk, reflects a UK-market origin that may influence how costs are structured for international or domestic licensees entering this system. Investors evaluating The Salt Room Nonexclusive franchise investment should treat the $199,100 to $483,100 range observed across comparable salt therapy franchise entrants as a reasonable planning envelope, while recognizing that nonexclusive models sometimes offer lower entry barriers in exchange for reduced territorial protection. The FPI Score for The Salt Room Nonexclusive is 38, which PeerSense classifies as Fair — a score that signals moderate performance indicators and invites additional scrutiny before capital commitment. SBA loan eligibility for wellness and outpatient care concepts varies by franchisor registration status, and prospective franchisees should confirm the eligibility status of The Salt Room Nonexclusive franchise directly before assuming conventional franchise financing pathways are available. Understanding what daily operations look like inside The Salt Room Nonexclusive franchise is essential for any investor assessing whether this model fits their operational profile and lifestyle requirements. Salt therapy facilities are fundamentally experience-driven wellness businesses, meaning the quality of the client-facing environment — ambient design, air quality management, halotherapy equipment calibration, and staff hospitality — directly determines customer retention and referral velocity. Staffing requirements in salt therapy operations are typically lean relative to other outpatient wellness categories, with the core team consisting of a studio manager and session attendants who guide clients through halotherapy rooms, manage equipment maintenance, and execute retail and membership sales. The Salt Suite's training benchmark — 56 hours of on-the-job training and 32 hours of classroom training — reflects the industry standard for getting a new salt therapy operator competent and confident before opening, and comparable training intensity would be expected from any credible system in this category. Corporate support in well-structured salt therapy franchises includes site selection guidance, buildout oversight, operations training, marketing training, and ongoing research and development access — the kind of comprehensive launch support that meaningfully reduces the new-operator learning curve. The Salt Rooms, operating out of Ireland, explicitly commits to teaching franchisees all necessary skills, systems, processes, and operational models, while Center of Salt Therapy provides expert training and ongoing support at every stage of development. For The Salt Room Nonexclusive franchise specifically, investors should confirm the precise training curriculum, field support cadence, and technology platform infrastructure available from the franchisor before signing, as nonexclusive models vary widely in the depth of operational scaffolding they provide. The ideal operator for this format is a hands-on owner rather than an absentee investor, given that the client experience is the product — and client experience quality is highly sensitive to owner engagement levels, particularly in a single-unit operation at early scale. Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for The Salt Room Nonexclusive franchise. This is a material fact for investors to understand clearly, because without Item 19 disclosure, no franchisor-verified average revenue, median revenue, or profit margin figures exist in the public record for this system. The FDD's non-disclosure of financial performance data is legally permitted — franchisors in the United States are not required to provide earnings representations in Item 19 — but it does shift the burden of financial modeling entirely onto the prospective franchisee. Industry revenue benchmarks for outpatient wellness and salt therapy operations provide a useful independent frame of reference. The global salt therapy market's projected $5.8 billion scale by 2027, divided across approximately 2,000 North American facilities, suggests average annual revenue per facility in the range of several hundred thousand dollars at current market penetration, with significant variance based on membership model sophistication, session pricing, retail attachment, and local market density. For comparable defined franchise systems, The Salt Suite does not disclose Item 19 data either, which means the broader salt therapy franchise category has limited public financial transparency — a pattern investors should weigh carefully. What the unit count trajectory signals is also relevant: The Salt Room Nonexclusive franchise operates at one total franchised unit, making it impossible to derive statistical performance distributions from the system's own historical data. The FPI Score of 38, categorized as Fair by PeerSense's independent methodology, reflects the combined effect of limited disclosure, early-stage unit count, and the structural characteristics of a nonexclusive licensing model. Prospective franchisees conducting The Salt Room Nonexclusive franchise revenue due diligence should request franchisee contact references, seek third-party benchmarks from the broader halotherapy industry, and model conservative, mid-range, and optimistic revenue scenarios using publicly available comparable data before drawing investment conclusions. The growth trajectory of The Salt Room Nonexclusive franchise reflects its current stage as a micro-scale operation with one franchised unit, which positions it fundamentally differently from mature franchise systems with hundreds of locations but offers a distinct set of potential advantages for early movers. The broader Salt Room network — the loosely affiliated ecosystem of licensed and independently operated Salt Room locations — has grown to 15 locations across the United States, demonstrating meaningful consumer proof-of-concept for the brand name and the service category even in the absence of a tightly centralized franchise infrastructure. The dry salt therapy industry itself is on an explosive growth curve: while European spas have integrated halotherapy as a standard service offering for decades, North American and Chinese markets are described by industry analysts as "virtually untapped," meaning the ceiling for category expansion is significantly higher than current unit counts suggest. For context on what category growth can look like in a defined salt therapy franchise system, The Salt Suite grew its franchisee outlet count from 2 locations in 2015 to 8 in 2022, reaching 9 total locations including one company-owned unit by 2023 — a trajectory that demonstrates the category can support franchise growth even within a single organized system. The competitive dynamics of the salt therapy category remain fragmented rather than consolidated, which creates both vulnerability to better-capitalized entrants and opportunity for established brand names like The Salt Room to leverage consumer recognition before institutional competitors arrive at scale. The Salt Room Nonexclusive franchise's UK-origin branding — reflected in its thesaltroom.co.uk web presence — may represent an international licensing strategy that differentiates it from U.S.-centric competitors, offering investors a globally connected brand narrative in a category where European heritage carries meaningful consumer credibility. Investors assessing The Salt Room Nonexclusive franchise opportunity should track new unit additions, territory expansion announcements, and any corporate-level developments in the parent organization's structure as key leading indicators of system momentum. The ideal franchisee profile for The Salt Room Nonexclusive franchise aligns closely with what the broader halotherapy industry has proven works: hands-on owner-operators with genuine passion for wellness outcomes, strong community relationship-building skills, and enough business acumen to manage membership sales, staffing, and operational consistency. Prior salt therapy industry experience is not a prerequisite — The Salt Suite explicitly states that no prior industry experience is necessary, emphasizing instead self-motivation and people management as the critical competencies — but experience in health, wellness, fitness, or hospitality services accelerates the learning curve substantially. Given that The Salt Room Nonexclusive franchise currently operates at one total unit, multi-unit growth expectations at the system level are nascent, but the nonexclusive licensing structure theoretically allows motivated operators to develop multiple locations without the territorial restrictions that exclusive franchise agreements impose. The franchise agreement term length, transfer terms, and renewal conditions are variables that prospective investors must review directly in the Franchise Disclosure Document, as these structural elements define the long-term value of the investment and the exit optionality available at resale. Markets performing best for salt therapy concepts historically skew toward health-conscious, higher-income suburban demographics with established wellness spending patterns — zip codes with strong yoga studio, boutique fitness, and integrative health clinic presence tend to correlate with successful halotherapy launches. The timeline from franchise signing to opening in comparable salt therapy concepts ranges from several months to over a year depending on site selection, buildout complexity, and equipment lead times, factors that investors should budget for both financially and psychologically before committing. The investment thesis for The Salt Room Nonexclusive franchise ultimately rests on a confluence of macro tailwinds, category-level proof of concept, and the inherent risks of an early-stage system with limited financial transparency. The global halotherapy market's projected $5.8 billion scale by 2027 and the broader outpatient care market's trajectory toward $157.5 billion by 2034 establish a category that is growing faster than most franchise categories available to investors today, and the brand's 15-location North American network demonstrates that consumer demand for The Salt Room experience is real and recurring. The FPI Score of 38 — classified as Fair by independent methodology — signals that this opportunity requires deeper investigation rather than surface-level enthusiasm, and the absence of Item 19 financial disclosure means investors cannot rely on franchisor-provided revenue data to anchor their modeling. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark The Salt Room Nonexclusive franchise against every other opportunity in the halotherapy and outpatient wellness category simultaneously. The combination of a legitimately high-growth wellness category, a recognizable brand name with consumer traction across 15 U.S. locations, and the structural flexibility of a nonexclusive licensing model creates an opportunity that sits outside the traditional franchise playbook — higher risk tolerance is required, but so is a more creative view of what franchise investment can look like at the frontier of an emerging category. Serious investors who are drawn to the salt therapy category should use every available analytical tool before committing capital, because the difference between a well-chosen and poorly-chosen location in a nascent wellness franchise can determine outcomes for years. Explore the complete The Salt Room Nonexclusive franchise profile on PeerSense to access the full suite of independent franchise intelligence data.